The treatment of opioid use disorder with buprenorphine and methadone reduces morbidity and mortality in patients with opioid use disorder. The initiation of buprenorphine in the emergency department (ED) has been associated with increased rates of outpatient treatment linkage and decreased drug use when compared to patients randomized to receive standard ED referral. As such, the ED has been increasingly recognized as a venue for the identification and initiation of treatment for opioid use disorder, but no formal American College of Emergency Physicians (ACEP) recommendations on the topic have previously been published. The ACEP convened a group of emergency physicians with expertise in clinical research, addiction, toxicology, and administration to review literature and develop consensus recommendations on the treatment of opioid use disorder in the ED. Based on literature review, clinical experience, and expert consensus, the group recommends that emergency physicians offer to initiate opioid use disorder treatment with buprenorphine in appropriate patients and provide direct linkage to ongoing treatment for patients with untreated opioid use disorder. These consensus recommendations include strategies for opioid use disorder treatment initiation and ED program implementation. They were approved by the ACEP board of directors in January 2021.

用丁丙诺啡和美沙酮治疗阿片类药物使用障碍可降低阿片类药物使用障碍患者的发病率和死亡率。与随机接受标准 ED 转诊的患者相比，急诊科 (ED) 开始使用丁丙诺啡与门诊治疗关联率增加和药物使用减少有关。因此，急诊室越来越被认为是识别和启动阿片类药物使用障碍治疗的场所，但此前美国急诊医师学会 (ACEP) 尚未发布关于该主题的正式建议。ACEP 召集了一组在临床研究、成瘾、毒理学、和管理部门审查文献并制定关于 ED 中阿片类药物使用障碍治疗的共识建议。根据文献回顾、临床经验和专家共识，该小组建议急诊医师在合适的患者中提供丁丙诺啡启动阿片类药物使用障碍治疗，并为未经治疗的阿片类药物使用障碍患者提供与正在进行的治疗的直接联系。这些共识建议包括阿片类药物使用障碍治疗启动和 ED 计划实施的策略。它们于 2021 年 1 月获得 ACEP 董事会的批准。该小组建议急诊医生主动提出在适当的患者中使用丁丙诺啡启动类阿片使用障碍治疗，并为未经治疗的类阿片使用障碍患者提供与正在进行的治疗的直接联系。这些共识建议包括阿片类药物使用障碍治疗启动和 ED 计划实施的策略。它们于 2021 年 1 月获得 ACEP 董事会的批准。该小组建议急诊医生主动提出在适当的患者中使用丁丙诺啡启动类阿片使用障碍治疗，并为未经治疗的类阿片使用障碍患者提供与正在进行的治疗的直接联系。这些共识建议包括阿片类药物使用障碍治疗启动和 ED 计划实施的策略。它们于 2021 年 1 月获得 ACEP 董事会的批准。